Sagimet Biosciences Inc
NASDAQ:SGMT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sagimet Biosciences Inc
NASDAQ:SGMT
|
US |
|
T
|
TTM Technologies Inc
DUS:TT1
|
US |
|
N
|
Netflix Inc
XMUN:NFC
|
US |
|
B
|
Beiersdorf AG
XMUN:BEI
|
DE |
|
Daito Trust Construction Co Ltd
OTC:DIFTY
|
JP |
|
D
|
Del Monte Corp
F:FDM
|
KY |
|
C
|
Camden Property Trust
F:CAL
|
US |
|
Sinclairs Hotels Ltd
NSE:SINCLAIR
|
IN |
|
Pointerra Ltd
OTC:PTRRF
|
AU |
Intrinsic Value
Is SGMT undervalued or overvalued?
See the intrinsic value estimate for Sagimet Biosciences Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Sagimet Biosciences Does
Sagimet Biosciences is a drug-development company focused on medicines that block fatty acid synthase, an enzyme tied to fat production in the body. Its lead program is denifanstat, an oral drug candidate being studied for liver disease and severe acne. The company does not sell a broad consumer product line; it develops prescription drug candidates and works to move them through clinical testing and regulatory approval.
- Headquarters
- United States of America US
- Employees
- 16
- IPO date
- Jul 14, 2023
Earnings Waterfall
Sagimet Biosciences Inc
The intrinsic value for Sagimet Biosciences Inc (SGMT) under the Base Case is hidden USD.
Compared with the current market price of 10.4 USD, the stock appears hidden.